Galen, the privately-owned pharmaceutical sales and marketing company, has announced that the application process for their Medical Nutrition Scholarship Award is now open.
The award, which is now in its second year, is designed to support people with metabolic disorders, such as Phenylketonuria (PKU) and Tyrosinaemia (TYR), in accessing further education, training and development courses or apprenticeships.
There are two scholarships on offer for people with metabolic disorders from across Europe, and each prize-winner will win a bursary of up to £2,000/€2,500 towards their education or training course support. The winners will also receive a full technology package worth £2,000 which includes a state-of-the-art laptop, monitor, tablet, Apple watch and AirPods.
The entry process, which is open until 26th August, includes the completion of an application form and a one-thousand-word personal statement, describing how the scholarship will enable applicants to achieve their personal and career goals.
The Galen Medical Nutrition Awards committee, including representatives from the metabolic disease community, will evaluate the entries and select two winners based on their submission, aspirations, and commitment to study.
Dr Dennise Broderick, Managing Director & President, Galen, said: “People who are born with metabolic disorders, such as PKU, and who receive the correct treatment can absolutely have the same educational and career goals as anyone else. Galen is committed to bringing innovation, quality and customer focus to people diagnosed with this condition and we are delighted to offer this scholarship programme again this year, by supporting and encouraging the aspirations of individuals who deserve the opportunity to fulfil their ambition.
Fergal Egan, Galen Medical Nutrition Scholarship Award Winner 2021 said: “If you are lucky enough to be chosen as I was, you will see clearly the profound impact it can have on achieving your goals.”
Ella Roberts, who also won the scholarship award last year, has recently completed a music degree at Cardiff University. She said: “I was a lucky recipient of Galen’s award last year. Galen has been very supportive to me, and the scholarship has helped me during my final year of studies to alleviate financial pressure. I would really encourage anyone who would like to study, to not let your metabolic condition hold you back and to apply for this award.”
Dr Broderick continued: “I would encourage people to apply for the scholarships and look forward to following how the winners progress over the course of their studies and beyond.”
Submissions must be made using the Galen Medical Nutrition Scholarship Award Entry Form –http://www.galenmedicalnutrition.com/scholarship-2022 and submitted via email to
About Galen Medical Nutrition
As a subsidiary of Galen Limited, Galen Medical Nutrition offer a variety of innovative medical foods, for use in the dietary management of metabolic disorders. Formulas are available for disorders such as Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), and Tyrosinemia (TYR) as well as Urea Cycle Disorders (UCD).
Galen Medical Nutrition is committed to bringing innovation, quality, and customer focus to people with metabolic disorders.
For further information please visit: www.galenmedicalnutrition.com
Galen is a privately owned pharmaceutical sales and marketing company, headquartered in Craigavon (Northern Ireland) and product presence in 25 locations covering each continent across the globe.
With over 50 years’ experience, we have 75+ products across a diverse range of therapy areas.
Galen has recently announced ambitious expansion plans across new territories and therapeutic areas through the acquisition of new company and product portfolios as well as product partnerships.
Galen aims to work in partnership with healthcare professionals and patients to create real, long-term value.
For further information please visit: www.galen-pharma.com
About Almac Group
Galen is the founding member of the Almac Group. The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across, and beyond, the drug development lifecycle to the pharmaceutical and biotech sectors globally.
The Group is wholly owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.
The international company is a privately owned organisation that has grown organically over the past five decades and now employs over 6,500 highly skilled personnel across 18 facilities including Europe, the US and Asia.
For further information please visit www.almacgroup.com.